(Reuters) – Drug developer Minerva Neurosciences Inc said on Friday its experimental drug for schizophrenia did not meet the main goal of a late-stage study.
The drug, roluperidone, did not show statistically significant difference from the placebo in reducing disease symptoms after 12 weeks of treatment, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)
